REVIEW

The Art of War: harnessing the epigenome against cancer

[version 1; peer review: 4 approved]

Jonathan Nye, Daniël P. Melters, Yamini Dalal

Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

V1 First published: 02 Feb 2018, 7(F1000 Faculty Rev):141
<https://doi.org/10.12688/f1000research.12833.1>

Latest published: 02 Feb 2018, 7(F1000 Faculty Rev):141
<https://doi.org/10.12688/f1000research.12833.1>

Abstract

Histone chaperones are indispensable regulators of chromatin structure and function. Recent work has shown that they are frequently mis-regulated in cancer, which can have profound consequences on tumor growth and survival. Here, we focus on chaperones for the essential H3 histone variants H3.3 and CENP-A, specifically HIRA, DAXX/ATRX, DEK, and HJURP. This review summarizes recent studies elucidating their roles in regulating chromatin and discusses how cancer-specific chromatin interactions can be exploited to target cancer cells.

Keywords

Epigenome, Histone chaperones, chromatin, cancer, tumor growth

Open Peer Review

Approval Status

	1	2	3	4
version 1 02 Feb 2018

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Zhiguo Zhang**, , Institute for Cancer Genetics, Irving Cancer Research Center, College of Surgeons and Physicians, Columbia University, New York, USA
2. **Peter Adams**, Beatson Institute for Canc, Glasgow, UK
3. **Genevieve Almouzni**, Institut Curie, PSL Research University, Paris, France
4. **Sandra B Hake**, Ludwig Maximilians University Munich, Munich, Germany

Any comments on the article can be found at the end of the article.

Corresponding author: Yamini Dalal (dalaly@mail.nih.gov)

Author roles: Nye J: Conceptualization, Writing – Original Draft Preparation; Melters DP: Writing – Original Draft Preparation; Dalal Y: Conceptualization, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: All authors were supported by the Intramural Research Program of the Center for Cancer Research at the National Cancer Institute

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2018 Nye J *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The author(s) is/are employees of the US Government and therefore domestic copyright protection in USA does not apply to this work. The work may be protected under the copyright laws of other jurisdictions when used in those jurisdictions.

How to cite this article: Nye J, Melters DP and Dalal Y. **The Art of War: harnessing the epigenome against cancer [version 1; peer review: 4 approved]** F1000Research 2018, 7(F1000 Faculty Rev):141 <https://doi.org/10.12688/f1000research.12833.1>

First published: 02 Feb 2018, 7(F1000 Faculty Rev):141 <https://doi.org/10.12688/f1000research.12833.1>

Introduction

Histones are a highly conserved family of proteins that facilitate the compaction of DNA by wrapping it around an octamer containing two copies each of the canonical histones H2A, H2B, H3, and H4. These canonical forms comprise the large majority of all histones bound to DNA and are responsible for the regulation of a variety of cellular processes including replication, transcription, and DNA repair. In addition, several histone variants have evolved to allow for additional levels of regulation. These variants can differ from their canonical counterparts in sequence, structure, and the timing of their incorporation. Canonical histone assembly is typically coupled to DNA replication at S-phase, whereas the assembly of histone variants is replication independent and spans all phases of the cell cycle¹.

Human histone variants have been identified for all canonical histones except for H4. The canonical histone H3 has six variants including H3.3, CENP-A, H3.1T, H3.5, H3.X, and H3.Y². This diversity allows for variants that specialize in a wide variety of different functions, including the regulation of transcription, chromosome segregation, and telomere function. Interestingly, the two most abundantly expressed and essential H3 variants differ not only in function but also in how much they have diverged from the canonical form. For example, the H3 variant H3.3 differs by five amino acids and shares 96.3% amino acid sequence similarity with its canonical counterpart H3.1; in

contrast, CENP-A exhibits only 45.1% similarity with H3.1². Furthermore, while their assembly is replication-independent, they localize to distinct regions of the genome: CENP-A is normally found predominantly at the centromere, whereas H3.3 localizes to heterochromatin, telomeres, enhancers, and genic areas of high nucleosome turnover (Figure 1).

The precise localization and assembly of these histones into chromatin is thought to be achieved through their interaction with histone variant specific chaperones by mechanisms not yet entirely elucidated. In addition, some chaperones are found to be closely associated with ATP-dependent chromatin remodelers. For example, proper H3.3 assembly and localization relies on the histone chaperone DAXX in complex with the SWI/SNF-like chromatin remodeler ATRX. Interestingly, H3.3 can associate with multiple chaperones, including HIRA and DEK, in addition to DAXX/ATRX. In contrast, human CENP-A normally associates with a single centromeric chaperone called HJURP. Intriguingly, while it has long been assumed that histone chaperones are mere carriers of histones, recent advances, including patient tumor sequencing data, have shown that these critical chaperones may play an unanticipated role in disease progression. Here, we review recent literature on this subject and ask how changes in variant chaperones can influence the histone variant chromatin landscape in the epigenome and thereby impact human health.

Figure 1. Histone chaperones allow for assembly at specific genomic regions. The histone variant H3.3 relies on three specific chaperones for deposition at specific locations in the genome. The chaperones DEK, DAXX/ATRX, and HIRA have been shown to prefer distinct sites for H3.3 assembly. Furthermore, they have been found to be mis-regulated in many cancer types, as shown. The centromeric histone variant CENP-A normally associates with a single chaperone called HJURP. However, changes in the amount of CENP-A compared to its chaperone can allow for deposition throughout chromosome arms by the H3.3 chaperone DAXX.

HIRA and senescence

The histone cell cycle regulator (HIRA) protein has been found to be a chaperone facilitating the assembly of the histone variant H3.3 into chromatin in a replication-independent manner³. It is at the center of a complex of proteins, conserved from yeast to humans, referred to as the HUCA complex that consists primarily of HIRA, UBN1, CABIN1, and transiently includes Asf1⁴. The UBN1 subunit imparts specificity to the complex by preferentially binding to H3.3/H4 over H3.1/H4, thereby enabling this dimer's assembly into chromatin⁵. Unlike other H3 variants like CENP-A, H3.3 normally associates with multiple chaperones and each complex appears to be responsible for its localization to specific places in the genome. For example, HIRA is necessary for H3.3 deposition at gene regulatory elements, gene bodies, and sites of DNA damage^{6,7}. Targeting of the HIRA complex is thought to be achieved through its interaction with a number of different proteins including transcription factors, chromatin remodelers, and the single-stranded DNA (ssDNA)-binding protein RPA^{6,8}. However, the precise mechanism by which this chaperone hones in on the correct regions of the genome has not been clearly elucidated. One possibility is that HIRA recruitment to gene regulatory regions requires the presence of R-loops. These RNA–DNA hybrid structures attract RPA owing to the presence of exposed ssDNA, which then recruits the HIRA complex and leads to H3.3 assembly at these sites. From these studies, it is clear that the HIRA complex is an important regulator of H3.3 deposition, but HIRA's role in human health is still unclear.

This is particularly intriguing because human HIRA was originally identified through the study of DiGeorge syndrome patients, who commonly have heart and brain abnormalities, arising from a deletion of the q11 cytogenetic band of chromosome 22, which contains the HIRA gene^{9,10}. Despite intense study, it is still unclear as to whether HIRA is responsible for these defects or if it is a result of the deletion of multiple genes. More recently, HIRA has been shown to have a clear role in establishing and maintaining senescence. Indeed, early studies discovered that HIRA and Asf1 are necessary for the formation of senescence-associated heterochromatic foci, which, in turn, are thought to be essential to shut down genes involved in cell cycle progression¹¹. Furthermore, the overexpression of HIRA and Asf1 is sufficient to induce senescence. In addition, post-translational modifications of HIRA have been identified and were shown to be necessary for its function. Consistent with HIRA's proposed role, the expression of a non-modifiable mutant led to defects in senescence¹². Multiple mechanisms have been proposed to explain the role of HIRA in the establishment of senescence. One provocative possibility involves a cleaved H3.3 protein lacking the first 21 amino acids. HIRA-mediated assembly of this cleaved protein has been shown to be sufficient to induce senescence and results in the repression of cell cycle regulators¹³. Other work has reported that HIRA is necessary for replication-independent deposition of H3.3 in senescent cells and for maintaining the H4K16ac histone mark at gene promoters^{14,15}. Furthermore, the same study found that HIRA was required to suppress oncogene-induced neoplasia in a mouse model. This work highlights the

importance of this H3.3 chaperone in fine tuning the chromatin environment to allow cells to permanently exit the cell cycle and preventing uncontrolled cell growth. As discussed in the next section, many questions remain unanswered: for instance, how is HIRA function affected by changes in levels of another H3.3 chaperone, DAXX, commonly observed in tumors? For example, can HIRA bind to other H3 variants as has been observed with DAXX? Furthermore, in Arabidopsis, H3.3 and DNA methylation are inversely related and H3.3 knockdown alters the DNA methylation profile^{16,17}. Moreover, it has been proposed that H3.3 prevents the recruitment of the linker histone H1¹⁸. These findings beg the following questions: can global changes in DNA methylation, coupled to widespread mis-regulation of linker histone H1 isoforms, both commonly associated with cancer, alter H3.3 deposition? Or, conversely, does gain or loss of H3.3 at a specific locus alter its DNA methylation profile? Both of these fundamental questions need to be addressed in future studies.

H3.3 deposition by DAXX/ATRX in cancer

The histone chaperone DAXX, or death domain-associated protein, was originally named for its association with the Fas receptor, wherein it was thought to induce apoptosis by activating the JNK pathway¹⁹. However, further work identified it as a bona fide H3.3 chaperone that forms a complex with the SWI/SNF-like chromatin remodeler ATRX^{20–22}. Like other H3.3 chaperones, ATRX/DAXX targets H3.3 to very specific regions of the genome in a replication-independent manner, specifically, to telomeres, pericentric heterochromatin, and other repetitive elements^{23–25}. Both ATRX and DAXX seem to be equally important in this process, with DAXX providing the H3.3 binding specificity and chaperone activity while ATRX targets the complex in part through binding to modified histones like H3K9me3 and also stretches of G-rich repeats with a unique secondary DNA structure called a G-quadruplex^{26–30}. Moreover, proper functioning of this complex is critical, since mutations in both of these proteins have been strongly linked to cancer and other diseases (Figure 2B, Table 1).

ATRX was first discovered by identifying mutations in patients with an inherited disorder, ATRX syndrome, which resulted in a wide array of developmental defects³¹. Since then, mutations in both ATRX and DAXX have been found in a variety of different tumor types and seem to be especially prevalent in tumors associated with the central nervous system^{32–35}. For example, in pediatric glioblastoma multiforme (GBM), 31% of patients have mutations in either ATRX or DAXX³⁶. It is unclear how these mutations are driving cancer in young patients, but it is likely that ATRX and DAXX deficiencies have adverse effects on chromatin structure that may contribute to the development of cancer. As has been noted in patient tumors, ATRX/DAXX deficiency is commonly associated with alternative lengthening of telomeres (ALT) pathway activation, in which telomere length is maintained in a telomerase-independent manner, allowing cell growth to continue on uncontrolled³⁷. Moreover, DAXX has also been shown to suppress lung cancer metastasis driven by the transcription factor Slug, directly binding to it, sequestering it,

Figure 2. Mutations in H3 variant chaperones occur in many cancer types. **A.** Percentage of cases affected by HIRA mutations in multiple cancer types obtained from The Cancer Genome Atlas (TCGA) analysis. Numbers listed above each bar represent total number of cases analyzed. TCGA cancer types listed in order from left to right include uterine corpus endometrial carcinoma (UCEC), skin cutaneous melanoma (SKCM), colon adenocarcinoma (COAD), stomach adenocarcinoma (STAD), urothelial bladder carcinoma (BLCA), head-neck squamous cell carcinoma (HNSC), lung squamous cell carcinoma (LUSC), glioblastoma multiforme (GBM), rectum adenocarcinoma (READ), and cholangiocarcinoma (CHOL). Locations of mutations within the HIRA protein. HIRA protein domains include a WD-40 repeat-containing domain, the B-domain (B) necessary for binding to Asf1, and the conserved Hir domain. **B.** DAXX mutations as above. TCGA cancer types listed in order from left to right include UCEC, SKCM, adrenocortical carcinoma (ACC), STAD, COAD, LUSC, BLCA, lung adenocarcinoma (LUAD), GBM, and READ. DAXX protein domains include the four-helix bundle (4HB) necessary for ATRX binding, a histone-binding domain, an acidic domain, and the Ser/Pro/Thr-rich region. **C.** DEK oncogene mutations listed as above. TCGA cancer types listed in order from left to right include UCEC, diffuse large B-cell lymphoma (DLBC), STAD, COAD, cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), BLCA, pancreatic adenocarcinoma (PAAD), SKCM, GBM, and ovarian cancer (OV). DEK protein domains shown include a DNA-binding domain, the scaffold attachment factor-box (SAF), and a DNA-binding and multimerization domain. **D.** HJURP mutations listed as above. TCGA cancer types listed in order from left to right include UCEC, SKCM, READ, STAD, COAD, CESC, OV, LUAD, uterine carcinosarcoma (UCS), and BLCA. HJURP protein domains include the SCM3 domain, the conserved domain (CD), the HJURP C-terminal domain (HCTD) responsible for centromere targeting, and the dimerization domain.

and preventing its association with DNA. Consequently, low DAXX expression levels correlated with lower overall survival in lung cancer patients with Slug expression³⁸.

While these studies conclude that DAXX activity may serve a cancer-protective function, recent work has shown, conversely, that the presence of DAXX in some cases may *enhance* tumor growth as well as generate resistance to treatment. For example, in GBM cells lacking the tumor suppressor PTEN, there is a DAXX-dependent increase in the expression of oncogenes, and inhibition of DAXX in this context can suppress tumor growth³⁹. DAXX has also been found to promote tumor growth

in a mouse xenograft model of prostate cancer⁴⁰. Furthermore, ONCOMINE meta-analysis revealed that overexpression of DAXX is common in prostate cancer patients and correlates with lower survival rates, suggesting that, in certain cases, DAXX may present itself as a viable therapeutic target.

One possibility is that chaperones might, in the cancer background, bind inappropriately to the wrong histone variant. Indeed, recent studies have shown that DAXX can bind to the centromeric histone variant CENP-A, which is naturally overexpressed in colorectal cancer cells. Indeed, both DAXX and ATRX are present at severalfold excess in these cells⁴¹. These data

Table 1. Expression changes of histone variant chaperones in cancer. ALT, alternative lengthening of telomeres; GBM, glioblastoma multiforme.

Histone Variant	Chaperone/Chromatin Remodeler	Cancer Expression Level	Functional Consequences	Refs
H3.3	HIRA	?	Decreased levels prevent senescence and increase oncogene-induced neoplasia in mouse model	14
	DAXX	Increased	Promotes tumor growth in mouse prostate cancer model	39
			Increased expression of oncogenes in GBM cells lacking PTEN	38
			Promotes mis-localization of CENP-A, leading to chromosomal instability	40–42
			Promotes proliferation and resistance to anticancer treatments	43
		Decreased	Potentiates Slug-driven lung cancer metastasis	37
	ATRX	Decreased	Activation of ALT pathway	36
	DEK	Increased	Upregulates anti-apoptotic factors	44
			Fusion protein dominant negative for DEK function	45–50
			Increased colony formation and tumorigenesis	51
CENP-A	HJURP	Increased	?	52–60
		Decreased	Chromosomal instability	61,62

suggest that serendipitous overexpression of chaperones alongside non-target histone variants might promote their association and drives mis-localization. Interestingly, this mis-localization has been shown to lead to genomic instability and also greater resistance to anticancer treatments^{42,43}. These findings may provide a mechanistic explanation for earlier data showing that DAXX appears to promote proliferation and chemoresistance in ovarian cancer cells⁶³.

From these studies, it is clear that the roles of DAXX and ATRX in cancer are complex and dependent on many factors, including the accompanying mutations, the tumor type, and alterations in histone variant expression. In the future, it will be important to understand exactly how changes in DAXX expression can drive cancer progression. It is likely that cells rely on a delicate balance between different chaperones. It will be interesting to test whether the phenotypes observed when DAXX is overexpressed are due to a titration of H3.3 away from HIRA, resulting in mis-regulation of gene regulatory elements, or defects in senescence, both thought to be controlled by that chaperone. If so, this would support a “chaperone competition” model, in which changes in chaperone expression lead to widespread changes in localization of their target histone variants and binding of

chaperones to non-cognate partners, thereby potentially driving tumorigenesis.

The proto-oncogene DEK

In addition to HIRA and DAXX, another H3.3 chaperone exists, namely the proto-oncogene DEK⁶⁴. DEK has been implicated in a wide variety of cellular processes including transcription, replication, and DNA repair⁶⁵. Interestingly, DEK also has the unique ability to bind preferentially to four-way junction DNA and induce positive supercoiling^{66,67}. In its role as an H3.3 chaperone, it has been shown to play a critical role in regulating the deposition of H3.3 by HIRA and ATRX/DAXX⁶⁸. Depletion of DEK in embryonic stem cells leads to the promiscuous incorporation of H3.3 throughout chromosome arms and pericentric heterochromatin by HIRA and DAXX. However, H3.3 is lost from telomeric chromatin and results in telomere dysfunction. Thus, DEK seems to behave as a gatekeeper, maintaining a balance between soluble and chromatin-bound H3.3 by modulating access to H3.3 by different chaperones.

As with the other chaperones, DEK overexpression can be found in many cancer types and correlates with increased proliferation and tumorigenesis (Table 1)^{42,44,69–74}. DEK may promote

tumorigenesis in multiple ways. First, it has been shown to prevent apoptosis by upregulating anti-apoptotic factors⁴⁵. Consequently, reducing DEK levels led to increased apoptosis and susceptibility to genotoxic agents in melanomas. Second, in acute myeloid leukemia, DEK has been reported to be the target of translocations that generate a fusion protein with NUP214^{46–50}. Precisely how this contributes to tumorigenesis is unclear; however, this fusion protein has been shown to interact with wild-type DEK and also inhibits chaperone activity⁶⁴. Third, DEK overexpression has been shown to inhibit senescence⁵¹. Indeed, DEK levels are reduced upon replicative senescence, and overexpression of the protein leads to prolonged lifespan. Consequently, DEK-knockout mice develop fewer tumors in a chemical carcinogenesis model, while overexpression leads to increased colony formation and tumorigenesis⁷⁵.

Since DEK is involved in so many different pathways, it will not be trivial to pin down exactly how, or whether, its overexpression promotes tumorigenesis via histone variant assembly pathways. One possibility involves its regulation of H3.3 assembly by HIRA and DAXX. Normally, DEK seems to function to counteract the assembly of H3.3 by these two complexes by maintaining the soluble pre-nucleosomal H3.3 pool⁶⁸. Thus, overexpression may prevent the proper assembly of this important histone variant by sequestering away H3.3 from HIRA or from DAXX. Indeed, it has been shown that depletion of HIRA leads to defects in senescence^{11–14}, which has also been shown in cases of DEK overexpression⁵¹.

The centromeric chaperone HJURP

The centromere-specific histone H3 variant CENP-A/CENH3 is the epigenetic mark that specifies the site for kinetochore assembly during mitosis⁷⁶. This allows for proper microtubule attachment to the chromosome and facilitates proper segregation of sister chromatids during anaphase. Like the H3.3 histone variant, CENP-A deposition occurs in a replication-independent manner. In human cells, the histone chaperone HJURP is responsible for its deposition during late mitosis/early G1^{61,77–78}. HJURP localization and licensing is tightly linked to cell cycle progression and requires phosphorylation by CDK/cyclin A^{79,80}. Both in the soluble preassembly complex and on chromatin, HJURP forms a homodimer⁸¹. Chromatin-bound HJURP is lost from centromeric chromatin by late G1/early S phase⁵², while a trace amount of it appears to return after replication, which may ensure that CENP-A can be deposited once and only once per cell cycle.

Like most other histone chaperones, the overexpression of HJURP has been observed in various cancers^{53–60}. In particular, breast, liver, and prostate cancer mis-regulate 14 centromere and kinetochore genes, including HJURP⁸²; this combinatorial mis-regulation has been proposed as a prognostic and predictive marker. These data also provide tantalizing functional links between cancer progression and mis-regulation of centromere chromatin because half of the 14 mis-regulated genes were found to be involved in the directed assembly of CENP-A nucleosomes. Interestingly, recent work has shown that the tumor suppressor p53 binds to elements in the promoters of CENP-A and HJURP

and serves to repress the expression of these genes. Thus, loss of p53, a common phenomenon in cancer, can result in the overexpression of HJURP and CENP-A⁶². Indeed, in colon cancer cells with a mutated *p53* gene, a DNase I hotspot maps to the CENP-A promoter, suggesting enhanced transcription of this gene, and correlates with increased RNA and protein levels of CENP-A⁴¹. This might explain why various types of tumors overexpress HJURP and CENP-A. In addition, a SNP located in the HJURP gene was found to be associated with increased risk for hepatocellular carcinoma among a Chinese population that were infected with hepatitis B virus⁸³. This correlated with a decrease in expression of HJURP at the mRNA and protein level.

These observations raise several questions. First, can changes in HJURP expression observed in cancer result in ectopic deposition of CENP-A? Indeed, in various cancers, ectopic CENP-A has been observed^{41,84}, and the overexpression of CENP-A has been shown to be sufficient for ectopic localization^{42,43}. Furthermore, this ectopic localization of CENP-A can result in chromosome instability. As noted above, CENP-A is deposited ectopically not by HJURP but by the H3.3 chaperone DAXX. This would suggest that when HJURP is limiting, CENP-A can bind promiscuously to other chaperones, allowing for ectopic localization⁸⁵. In addition, ectopic CENP-A nucleosomes can form highly stable heterotypic CENP-A/H3.3 nucleosomes^{41,42,86}. The origin, and consequences, of these heterotypic hybrid nucleosomes *in vivo* is a focus of intense studies. One possibility is that CENP-A is able to associate directly with DAXX but requires HJURP as an intermediate chaperone. Another possibility is that upon HJURP overexpression, DAXX and HJURP can form a heterodimer analogous to the HJURP homodimer, leading to the formation of these heterotypic nucleosomes⁸¹. Finally, in high-turnover regions, H3.3 nucleosomes are thought to ‘split’ in half during transit of RNA polymerases^{87–89}, providing a tantalizing means for invasion of an existing H3.3 nucleosome by a dimer of CENP-A/H4.

Second, can mutations in CENP-A’s protein sequence, or in the gain or loss of specific post-translational modifications, alter its affinity for HJURP in cancer? Recently, a modification of CENP-A through acetylation and ubiquitination of lysine 124 as well as phosphorylation of serine 68 was discovered^{52,90–93}. Interestingly, ubiquitination of K124 and phosphorylation of S68 seem to play antagonistic roles, the first being necessary for HJURP binding and the latter inhibiting it, resulting in enhanced ectopic localization^{93,94}. In addition, recent work has shown that when the tumor suppressor Fbw7 is lost, CENP-A S18 becomes hyper-phosphorylated, leading to chromosomal instability and tumor progression as a result of reduced CENP-A at centromeres⁹⁵. It is clear from this work that the proper localization and function of CENP-A relies on modifications that either enhance or reduce its affinity for the chaperone HJURP. However, it is also likely that cancer cells exploit these pathways to promote tumor growth. In the future, it will be interesting to investigate whether this occurs for other H3 variants as well. For example, pre-assembly H3.3/H4 heterodimers have also been shown to be modified, but it is unclear whether these modifications are altered in tumors^{96,97}.

Conclusion

A major problem when trying to identify specific mechanisms that promote tumorigenesis is that even seemingly subtle changes, such as point mutations in a chaperone (Figure 2), can dramatically alter the epigenetic landscape of a tumor³⁶. Therefore, in the battle against cancer, the enemy has an apparent advantage. Indeed, in this regard, cancer cells appear to have mastered the maxim, “be extremely subtle, even to the point of formlessness... thereby you can be the director of the opponent’s fate” (Sun Tzu, *The Art of War*).

The crucial question is whether the chaperone–histone misinteractions listed above, driven by mutation, mis-expression, or mis-regulation, can serve as therapeutic targets in the treatment of disease⁹⁸. What makes such interactions an attractive target is precisely that they do not exist in normal cells. Thus, there are likely a small set of critical interactions that might be meaningful to exploit. Consequently, it will be informative to test whether identifying and blocking cancer-specific interactions between histone variants and chaperones, such as DAXX binding to CENP-A, or between chaperones and chromatin regulatory complexes can serve as a potent method to singularly

attack cancer-specific networks while sparing normal cells. In this quest, using advanced techniques such as molecular docking, computational modeling, sophisticated machine-learning algorithms to query mutated protein interactomes, and focused small molecule design to identify and disrupt local affinities in protein–protein or DNA–protein interactions presents exciting and promising avenues of research. Thus, in our battle against disease, we note another maxim that promises hope: “in the midst of chaos, there is also opportunity” (Sun Tzu, *The Art of War*).

Competing interests

The authors declare that they have no competing interests.

Grant information

All authors were supported by the Intramural Research Program of the Center for Cancer Research at the National Cancer Institute, National Institutes of Health.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

- Szenker E, Ray-Gallet D, Almouzni G: **The double face of the histone variant H3.3.** *Cell Res.* 2011; **21**(3): 421–34.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Buschbeck M, Hake SB: **Variants of core histones and their roles in cell fate decisions, development and cancer.** *Nat Rev Mol Cell Biol.* 2017; **18**(5): 299–314.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Tagami H, Ray-Gallet D, Almouzni G, *et al.*: **Histone H3.1 and H3.3 complexes mediate nucleosome assembly pathways dependent or independent of DNA synthesis.** *Cell.* 2004; **116**(1): 51–61.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- Banumathy G, Somaiah N, Zhang R, *et al.*: **Human UBN1 is an ortholog of yeast Hpc2p and has an essential role in the HIRA/ASF1a chromatin-remodeling pathway in senescent cells.** *Mol Cell Biol.* 2009; **29**(3): 758–70.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Ricketts MD, Frederick B, Hoff H, *et al.*: **Ubinuclein-1 confers histone H3.3-specific-binding by the HIRA histone chaperone complex.** *Nat Commun.* 2015; **6**: 7711.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- Pchelintsev NA, McBryan T, Rai TS, *et al.*: **Placing the HIRA histone chaperone complex in the chromatin landscape.** *Cell Rep.* 2013; **3**(4): 1012–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Adam S, Polo SE, Almouzni G: **Transcription recovery after DNA damage requires chromatin priming by the H3.3 histone chaperone HIRA.** *Cell.* 2013; **155**(1): 94–106.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Zhang H, Gan H, Wang Z, *et al.*: **RPA Interacts with HIRA and Regulates H3.3 Deposition at Gene Regulatory Elements in Mammalian Cells.** *Mol Cell.* 2017; **65**(2): 272–84.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- Roberts C, Daw SC, Halford S, *et al.*: **Cloning and developmental expression analysis of chick *Hira* (*Chira*), a candidate gene for DiGeorge syndrome.** *Hum Mol Genet.* 1997; **6**(2): 237–45.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Farrell MJ, Stadt H, Wallis KT, *et al.*: **HIRA, a DiGeorge syndrome candidate gene, is required for cardiac outflow tract septation.** *Circ Res.* 1999; **84**(2): 127–35.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Zhang R, Poustovoitov MV, Ye X, *et al.*: **Formation of MacroH2A-containing senescence-associated heterochromatin foci and senescence driven by ASF1a and HIRA.** *Dev Cell.* 2005; **8**(1): 19–30.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Lee JS, Zhang Z: **O-linked N-acetylglucosamine transferase (OGT) interacts with the histone chaperone HIRA complex and regulates nucleosome assembly and cellular senescence.** *Proc Natl Acad Sci U S A.* 2016; **113**(23): E3213–20.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Duarte LF, Young AR, Wang Z, *et al.*: **Histone H3.3 and its proteolytically processed form drive a cellular senescence programme.** *Nat Commun.* 2014; **5**: 5210.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Rai TS, Cole JJ, Nelson DM, *et al.*: **HIRA orchestrates a dynamic chromatin landscape in senescence and is required for suppression of neoplasia.** *Genes Dev.* 2014; **28**(24): 2712–25.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Elsheikh SE, Green AR, Rakha EA, *et al.*: **Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome.** *Cancer Res.* 2009; **69**(9): 3802–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Stroud H, Otero S, Desvoves B, *et al.*: **Genome-wide analysis of histone H3.1 and H3.3 variants in *Arabidopsis thaliana*.** *Proc Natl Acad Sci U S A.* 2012; **109**(14): 5370–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Wollmann H, Stroud H, Yelagandula R, *et al.*: **The histone H3 variant H3.3 regulates gene body DNA methylation in *Arabidopsis thaliana*.** *Genome Biol.* 2017; **18**(1): 94.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Braunschweig U, Hogan GJ, Pagie L, *et al.*: **Histone H1 binding is inhibited by histone variant H3.3.** *EMBO J.* 2009; **28**(23): 3635–45.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Yang X, Khosravi-Far R, Chang HY, *et al.*: **Daxx, a novel Fas-binding protein that activates JNK and apoptosis.** *Cell.* 1997; **89**(7): 1067–76.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Xue Y, Gibbons R, Yan Z, *et al.*: **The ATRX syndrome protein forms a chromatin-remodeling complex with Daxx and localizes in promyelocytic leukemia nuclear bodies.** *Proc Natl Acad Sci U S A.* 2003; **100**(19): 10635–40.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Tang J, Wu S, Liu H, *et al.*: **A novel transcription regulatory complex containing death domain-associated protein and the ATR-X syndrome protein.** *J Biol Chem.* 2004; **279**(19): 20369–77.
[PubMed Abstract](#) | [Publisher Full Text](#)

22. Elsässer SJ, Huang H, Lewis PW, *et al.*: **DAXX envelops a histone H3.3-H4 dimer for H3.3-specific recognition.** *Nature*. 2012; 491(7425): 560–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
23. Goldberg AD, Banaszynski LA, Noh KM, *et al.*: **Distinct factors control histone variant H3.3 localization at specific genomic regions.** *Cell*. 2010; 140(5): 678–91.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
24. Drané P, Ouarrakhi K, Depaux A, *et al.*: **The death-associated protein DAXX is a novel histone chaperone involved in the replication-independent deposition of H3.3.** *Genes Dev*. 2010; 24(12): 1253–65.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
25. Lewis PW, Elsaesser SJ, Noh KM, *et al.*: **Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres.** *Proc Natl Acad Sci U S A*. 2010; 107(32): 14075–80.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
26. Dhayalan A, Tamas R, Bock I, *et al.*: **The ATRX-ADD domain binds to H3 tail peptides and reads the combined methylation state of K4 and K9.** *Hum Mol Genet*. 2011; 20(11): 2195–203.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
27. Eustermann S, Yang JC, Law MJ, *et al.*: **Combinatorial readout of histone H3 modifications specifies localization of ATRX to heterochromatin.** *Nat Struct Mol Biol*. 2011; 18(7): 777–82.
[PubMed Abstract](#) | [Publisher Full Text](#)
28. Iwase S, Xiang B, Ghosh S, *et al.*: **ATRX ADD domain links an atypical histone methylation recognition mechanism to human mental-retardation syndrome.** *Nat Struct Mol Biol*. 2011; 18(7): 769–76.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
29. **F** Law MJ, Lower KM, Voon HP, *et al.*: **ATR-X syndrome protein targets tandem repeats and influences allele-specific expression in a size-dependent manner.** *Cell*. 2010; 143(3): 367–78.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
30. Liu CP, Xiong C, Wang M, *et al.*: **Structure of the variant histone H3.3-H4 heterodimer in complex with its chaperone DAXX.** *Nat Struct Mol Biol*. 2012; 19(12): 1287–92.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
31. Gibbons RJ, Higgs DR: **Molecular-clinical spectrum of the ATR-X syndrome.** *Am J Med Genet*. 2000; 97(3): 204–12.
[PubMed Abstract](#) | [Publisher Full Text](#)
32. **F** Jiao Y, Shi C, Edil BH, *et al.*: **DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.** *Science*. 2011; 331(6021): 1199–203.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
33. Khuong-Quang DA, Buczkowicz P, Rakopoulos P, *et al.*: **K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas.** *Acta Neuropathol*. 2012; 124(3): 439–47.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
34. **F** Johnson BE, Mazar T, Hong C, *et al.*: **Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.** *Science*. 2014; 343(6167): 189–93.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
35. **F** Wu G, Diaz AK, Paugh BS, *et al.*: **The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma.** *Nat Genet*. 2014; 46(5): 444–50.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
36. **F** Schwartzentruber J, Korshunov A, Liu XY, *et al.*: **Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma.** *Nature*. 2012; 482(7384): 226–31.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
37. Heaphy CM, de Wilde RF, Jiao XY, *et al.*: **Altered telomeres in tumors with ATRX and DAXX mutations.** *Science*. 2011; 333(333): 425.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
38. Lin CW, Wang LK, Wang SP, *et al.*: **Daxx inhibits hypoxia-induced lung cancer cell metastasis by suppressing the HIF-1 α /HDAC1/Slug axis.** *Nat Commun*. 2016; 7: 13867.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
39. **F** Benitez JA, Ma J, D'Antonio M, *et al.*: **PTEN regulates glioblastoma oncogenesis through chromatin-associated complexes of DAXX and histone H3.3.** *Nat Commun*. 2017; 8: 15223.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
40. Puto LA, Brognard J, Hunter T: **Transcriptional Repressor DAXX Promotes Prostate Cancer Tumorigenicity via Suppression of Autophagy.** *J Biol Chem*. 2015; 290(25): 15406–20.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
41. Athwal RK, Walkiewicz MP, Baek S, *et al.*: **CENP-A nucleosomes localize to transcription factor hotspots and subtelomeric sites in human cancer cells.** *Epigenetics Chromatin*. 2015; 8: 2.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
42. Lacoste N, Woolfe A, Tachiwana H, *et al.*: **Mislocalization of the centromeric histone variant CenH3/CENP-A in human cells depends on the chaperone DAXX.** *Mol Cell*. 2014; 53(4): 631–44.
[PubMed Abstract](#) | [Publisher Full Text](#)
43. Shrestha RL, Ahn GS, Staples MI, *et al.*: **Mislocalization of centromeric histone H3 variant CENP-A contributes to chromosomal instability (CIN) in human cells.** *Oncotarget*. 2017; 8(29): 46781–800.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
44. Nakashima T, Tomita H, Hirata A, *et al.*: **Promotion of cell proliferation by the proto-oncogene DEK enhances oral squamous cell carcinogenesis through field cancerization.** *Cancer Med*. 2017; 6(10): 2424–39.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
45. Khodadoust MS, Verhaegen M, Kappes F, *et al.*: **Melanoma proliferation and chemoresistance controlled by the DEK oncogene.** *Cancer Res*. 2009; 69(16): 6405–13.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
46. von Linder M, Fornerod M, van Baal S, *et al.*: **The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia-specific dek-can mRNA.** *Mol Cell Biol*. 1992; 12(4): 1687–97.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
47. Saito S, Cigdem S, Okuwaki M, *et al.*: **Leukemia-Associated Nup214 Fusion Proteins Disturb the XPO1-Mediated Nuclear-Cytoplasmic Transport Pathway and Thereby the NF- κ B Signaling Pathway.** *Mol Cell Biol*. 2016; 36(13): 1820–35.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
48. Piredda ML, Catalano G, Ciardi C, *et al.*: **Identification of a potential topoisomerase II “hotspot” DNA region in the DEK gene in two t(6;9)-positive therapy-related myeloid neoplasms.** *Ann Hematol*. 2017; 96(1): 155–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
49. Qin H, Malek S, Cowell JK, *et al.*: **Transformation of human CD34+ hematopoietic progenitor cells with DEK-NUP214 induces AML in an immunocompromised mouse model.** *Oncogene*. 2016; 35(43): 5686–91.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
50. Campregher PV, Halley ND, Vieira GA, *et al.*: **Identification of a novel fusion TBL1XR1-PDGFRB in a patient with acute myeloid leukemia harboring the DEK-NUP214 fusion and clinical response to dasatinib.** *Leuk Lymphoma*. 2017; 58(12): 2969–72.
[PubMed Abstract](#) | [Publisher Full Text](#)
51. Wise-Draper TM, Allen HV, Thobe MN, *et al.*: **The human DEK proto-oncogene is a senescence inhibitor and an upregulated target of high-risk human papillomavirus E7.** *J Virol*. 2005; 79(22): 14309–17.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
52. Bui M, Dimitriadis EK, Hoischen C, *et al.*: **Cell-cycle-dependent structural transitions in the human CENP-A nucleosome in vivo.** *Cell*. 2012; 150(2): 317–26.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
53. Hu Z, Huang G, Sadanandam A, *et al.*: **The expression level of HJURP has an independent prognostic impact and predicts the sensitivity to radiotherapy in breast cancer.** *Breast Cancer Res*. 2010; 12(2): R18.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
54. Hu B, Wang Q, Wang Y, *et al.*: **Holliday junction-recognizing protein promotes cell proliferation and correlates with unfavorable clinical outcome of hepatocellular carcinoma.** *Onco Targets Ther*. 2017; 10: 2601–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
55. Rouam S, Moreau T, Broët P: **Identifying common prognostic factors in genomic cancer studies: a novel index for censored outcomes.** *BMC Bioinformatics*. 2010; 11: 150.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
56. Valente V, Serafim RB, de Oliveira LC, *et al.*: **Modulation of HJURP (Holliday Junction-Recognizing Protein) levels is correlated with glioblastoma cells survival.** *PLoS One*. 2013; 8(4): e62200.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
57. de Tayrac M, Saikali S, Aubry M, *et al.*: **Prognostic significance of EDN/RB, HJURP, p60/CAF-1 and PDL1, four new markers in high-grade gliomas.** *PLoS One*. 2013; 8(9): e73332.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
58. Montes de Oca R, Gurard-Levin ZA, Berger F, *et al.*: **The histone chaperone HJURP is a new independent prognostic marker for luminal A breast carcinoma.** *Mol Oncol*. 2015; 9(3): 657–74.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
59. Zhou D, Tang W, Liu X, *et al.*: **Clinical verification of plasma messenger RNA as novel noninvasive biomarker identified through bioinformatics analysis for lung cancer.** *Oncotarget*. 2017; 8(27): 43978–89.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
60. Cao R, Wang G, Qian K, *et al.*: **Silencing of HJURP induces dysregulation of cell cycle and ROS metabolism in bladder cancer cells via PPAR γ -SIRT1 feedback loop.** *J Cancer*. 2017; 8(12): 2282–95.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
61. **F** Jansen LE, Black BE, Foltz DR, *et al.*: **Propagation of centromeric chromatin requires exit from mitosis.** *J Cell Biol*. 2007; 176(6): 795–805.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
62. **F** Filipescu D, Naughtin M, Podsypanina K, *et al.*: **Essential role for centromeric factors following p53 loss and oncogenic transformation.** *Genes Dev*. 2017; 31(5): 463–80.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
63. Pan WW, Zhou JJ, Liu XM, *et al.*: **Death domain-associated protein DAXX promotes ovarian cancer development and chemoresistance.** *J Biol Chem*. 2013; 288(19): 13620–30.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

64. Sawatsubashi S, Murata T, Lim J, *et al.*: **A histone chaperone, DEK, transcriptionally coactivates a nuclear receptor.** *Genes Dev.* 2010; **24**(2): 159–70. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
65. Sandén C, Gullberg U: **The DEK oncoprotein and its emerging roles in gene regulation.** *Leukemia.* 2015; **29**(8): 1632–6. [PubMed Abstract](#) | [Publisher Full Text](#)
66. Böhm F, Kappes F, Scholten I, *et al.*: **The SAF-box domain of chromatin protein DEK.** *Nucleic Acids Res.* 2005; **33**(3): 1101–10. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
67. Waldmann T, Eckerich C, Baack M, *et al.*: **The ubiquitous chromatin protein DEK alters the structure of DNA by introducing positive supercoils.** *J Biol Chem.* 2002; **277**(28): 24988–94. [PubMed Abstract](#) | [Publisher Full Text](#)
68. Ivanauskienė K, Delbarre E, McGhie JD, *et al.*: **The PML-associated protein DEK regulates the balance of H3.3 loading on chromatin and is important for telomere integrity.** *Genome Res.* 2014; **24**(10): 1584–94. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
69. Xu X, Zou L, Yao Q, *et al.*: **Silencing DEK downregulates cervical cancer tumorigenesis and metastasis via the DEK/p-Ser9-GSK-3β/p-Tyr216-GSK-3β/β-catenin axis.** *Oncol Rep.* 2017; **38**(2): 1035–42. [PubMed Abstract](#) | [Publisher Full Text](#)
70. Feng T, Liu Y, Li C, *et al.*: **DEK proto-oncogene is highly expressed in astrocytic tumors and regulates glioblastoma cell proliferation and apoptosis.** *Tumour Biol.* 2017; **39**(7): 1010428317716248. [PubMed Abstract](#) | [Publisher Full Text](#)
71. Sun J, Bi F, Yang Y, *et al.*: **DEK protein overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma.** *Oncol Rep.* 2017; **37**(2): 857–64. [PubMed Abstract](#) | [Publisher Full Text](#)
72. Qiao MX, Li C, Zhang AQ, *et al.*: **Regulation of DEK expression by AP-2α and methylation level of DEK promoter in hepatocellular carcinoma.** *Oncol Rep.* 2016; **36**(4): 2382–90. [PubMed Abstract](#) | [Publisher Full Text](#)
73. Ou Y, Xia R, Kong F, *et al.*: **Overexpression of DEK is an indicator of poor prognosis in patients with gastric adenocarcinoma.** *Oncol Lett.* 2016; **11**(3): 1823–8. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
74. Yu L, Huang X, Zhang W, *et al.*: **Critical role of DEK and its regulation in tumorigenesis and metastasis of hepatocellular carcinoma.** *Oncotarget.* 2016; **7**(18): 26844–55. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
75. Wise-Draper TM, Mintz-Cole RA, Morris TA, *et al.*: **Overexpression of the cellular DEK protein promotes epithelial transformation in vitro and in vivo.** *Cancer Res.* 2009; **69**(5): 1792–9. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
76. Henikoff S, Furuyama T: **Epigenetic inheritance of centromeres.** *Cold Spring Harb Symp Quant Biol.* 2010; **75**: 51–60. [PubMed Abstract](#) | [Publisher Full Text](#)
77. Foltz DR, Jansen LE, Bailey AO, *et al.*: **Centromere-specific assembly of CENP-A nucleosomes is mediated by HJURP.** *Cell.* 2009; **137**(3): 472–84. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
78. Shuaib M, Ouararhni K, Dimitrov S, *et al.*: **HJURP binds CENP-A via a highly conserved N-terminal domain and mediates its deposition at centromeres.** *Proc Natl Acad Sci U S A.* 2010; **107**(4): 1349–54. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
79. Silva MC, Bodor DL, Stellfox ME, *et al.*: **Cdk activity couples epigenetic centromere inheritance to cell cycle progression.** *Dev Cell.* 2012; **22**(1): 52–63. [PubMed Abstract](#) | [Publisher Full Text](#)
80. **F** Stankovic A, Guo LY, Mata JF, *et al.*: **A Dual Inhibitory Mechanism Sufficient to Maintain Cell-Cycle-Restricted CENP-A Assembly.** *Mol Cell.* 2017; **65**(2): 231–46. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
81. Zasadzńska E, Barnhart-Dailey MC, Kuich PH, *et al.*: **Dimerization of the CENP-A assembly factor HJURP is required for centromeric nucleosome deposition.** *EMBO J.* 2013; **32**(15): 2113–24. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
82. Zhang W, Mao JH, Zhu W, *et al.*: **Centromere and kinetochore gene misexpression predicts cancer patient survival and response to radiotherapy and chemotherapy.** *Nat Commun.* 2016; **7**: 12619. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
83. Huang W, Zhang H, Hao Y, *et al.*: **A Non-Synonymous Single Nucleotide Polymorphism in the HJURP Gene Associated with Susceptibility to Hepatocellular Carcinoma among Chinese.** *PLoS One.* 2016; **11**(2): e0148618. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
84. Tomonaga T, Matsushita K, Yamaguchi S, *et al.*: **Overexpression and mistargeting of centromere protein-A in human primary colorectal cancer.** *Cancer Res.* 2003; **63**(13): 3511–6. [PubMed Abstract](#)
85. Melters DP, Nye J, Zhao H, *et al.*: **Chromatin Dynamics in Vivo: A Game of Musical Chairs.** *Genes (Basel).* 2015; **6**(3): 751–76. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
86. **F** Arimura Y, Shirayama K, Horikoshi N, *et al.*: **Crystal structure and stable property of the cancer-associated heterotypic nucleosome containing CENP-A and H3.3.** *Sci Rep.* 2014; **4**(1): 7115. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
87. Xu M, Long C, Chen X, *et al.*: **Partitioning of histone H3-H4 tetramers during DNA replication-dependent chromatin assembly.** *Science.* 2010; **328**(5974): 94–8. [PubMed Abstract](#) | [Publisher Full Text](#)
88. **F** Huang C, Zhang Z, Xu M, *et al.*: **H3.3-H4 tetramer splitting events feature cell-type specific enhancers.** *PLoS Genet.* 2013; **9**(6): e1003558. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
89. **F** Katan-Khaykovich Y, Struhl K: **Splitting of H3-H4 tetramers at transcriptionally active genes undergoing dynamic histone exchange.** *Proc Natl Acad Sci U S A.* 2011; **108**(4): 1296–301. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
90. Bui M, Pitman M, Nuccio A, *et al.*: **Internal modifications in the CENP-A nucleosome modulate centromeric dynamics.** *Epigenetics Chromatin.* 2017; **10**: 17. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
91. **F** Niikura Y, Kitagawa R, Kitagawa K: **CENP-A Ubiquitylation Is Inherited through Dimerization between Cell Divisions.** *Cell Rep.* 2016; **15**(1): 61–76. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
92. Niikura Y, Kitagawa R, Kitagawa K: **CENP-A Ubiquitylation Is Required for CENP-A Deposition at the Centromere.** *Dev Cell.* 2017; **40**(1): 7–8. [PubMed Abstract](#) | [Publisher Full Text](#)
93. **F** Yu Z, Zhou X, Wang W, *et al.*: **Dynamic phosphorylation of CENP-A at Ser68 orchestrates its cell-cycle-dependent deposition at centromeres.** *Dev Cell.* 2015; **32**(1): 68–81. [PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
94. Zhao H, Winogradoff D, Bui M, *et al.*: **Promiscuous Histone Mis-Assembly Is Actively Prevented by Chaperones.** *J Am Chem Soc.* 2016; **138**(40): 13207–18. [PubMed Abstract](#) | [Publisher Full Text](#)
95. **F** Takada M, Zhang W, Suzuki A, *et al.*: **FBW7 Loss Promotes Chromosomal Instability and Tumorigenesis via Cyclin E1/CDK2-Mediated Phosphorylation of CENP-A.** *Cancer Res.* 2017; **77**(18): 4881–93. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
96. **F** Loyola A, Bonaldi T, Roche D, *et al.*: **PTMs on H3 variants before chromatin assembly potentiate their final epigenetic state.** *Mol Cell.* 2006; **24**(2): 309–16. [PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
97. Kang B, Pu M, Hu G, *et al.*: **Phosphorylation of H4 Ser 47 promotes HIRA-mediated nucleosome assembly.** *Genes Dev.* 2011; **25**(13): 1359–64. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
98. Quénet D, Walkiewicz M, Dalal Y: **Chromatin at the Intersection of Disease and Therapy.** In *Toxicology and Epigenetics.* John Wiley & Sons, Ltd. 2012; 51–71. [Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

- Sandra B Hake**
Center for Integrated Protein Science Munich (CIPSM), Ludwig Maximilians University Munich, Munich, Germany
Competing Interests: No competing interests were disclosed.
- Genevieve Almouzni**
Equipe Labellisée Ligue contre le Cancer; Sorbonne Universités, Institut Curie, PSL Research University, Paris, France
Competing Interests: No competing interests were disclosed.
- Peter Adams**
Beatson Institute for Canc, Glasgow, UK
Competing Interests: No competing interests were disclosed.
- Zhiguo Zhang**
Departments of Pediatrics and Genetics and Development, , Institute for Cancer Genetics, Irving Cancer Research Center, College of Surgeons and Physicians, Columbia University, New York, USA
Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research